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Background: Flattening filter-free (FFF) linear accelerators (linacs) are capable of delivering dose rates more than 4-
times higher than conventional linacs during SBRT treatments, causing some to speculate whether the higher dose
rate leads to increased toxicity owing to radiobiological dose rate effects. Despite wide clinical use of this emerging
technology, clinical toxicity data for FFF SBRT are lacking. In this retrospective study, we report the acute and late
toxicities observed in our lung radiosurgery experience using a FFF linac operating at 2400 MU/min.
Methods: We reviewed all flattening filter-free (FFF) lung SBRT cases treated at our institution from August 2010
through July 2012. Patients were eligible for inclusion if they had at least one clinical assessment at least 30 days
following SBRT. Pulmonary, cardiac, dermatologic, neurologic, and gastrointestinal treatment related toxicities were
scored according to CTCAE version 4.0. Toxicity observed within 90 days of SBRT was categorized as acute, whereas
toxicity observed more than 90 days from SBRT was categorized as late. Factors thought to influence risk of toxicity
were examined to assess relationship to grade > =2 toxicity.
Results: Sixty-four patients with >30 day follow up were eligible for inclusion. All patients were treated using 10
MV unflattened photons beams with intensity modulated radiation therapy (IMRT) inverse planning. Median SBRT
dose was 48 Gy in 4 fractions (range: 30–60 Gy in 3–5 fractions). Six patients (9%) experienced > = grade 2 acute
pulmonary toxicity; no non-pulmonary acute toxicities were observed. In a subset of 49 patients with greater than
90 day follow up (median 11.5 months), 11 pulmonary and three nerve related grade > =2 late toxicities were
recorded. Pulmonary toxicities comprised six grade 2, three grade 3, and one each grade 4 and 5 events. Nerve
related events were rare and included two cases of grade 2 chest wall pain and one grade 3 brachial plexopathy
which spontaneously resolved. No grade > =2 late gastrointestinal, skin, or cardiac toxicities were observed. Tumor
size, biologically effective dose (BED10, assuming α/β of 10), and tumor location (central vs peripheral) were not
significantly associated with grade > =2 toxicity.
Conclusions: In this early clinical experience, lung SBRT using a FFF linac operating at 2400 MU/min yields minimal
acute toxicity. Preliminary results of late treatment related toxicity suggest reasonable rates of grade > =2 toxicities.
Further assessment of late effects and confirmation of the clinical efficacy of FFF SBRT is warranted.
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Stereotactic Body Radiation Therapy (SBRT) involves
precise delivery of ablative radiation doses to localized
malignancies using concomitant image guidance and/or
target tracking. Based on successful early clinical results
from phase I and II clinical trials, SBRT has become a
common treatment strategy for small primary or meta-
static lesions in the lung [1-6]. Despite the advantage of
a shortened treatment course compared to convention-
ally fractionated radiotherapy, the lengthy time required
to deliver each high dose treatment fraction is undesir-
able for immobilized patients and supervising physicians
alike. More importantly, prolonged treatment sessions
may contribute to intra-fraction motion [7] due to pa-
tient discomfort in the treatment position, thereby jeop-
ardizing the delicate therapeutic index of high dose
radiation treatment.
In an effort to shorten SBRT treatment delivery time,
manufacturers have developed flattening filter-free (FFF)
linacs capable of delivering roughly 4-times higher dose
rates compared to conventional linacs with flattened
beams (Figure 1). Preclinical data using phantom deliv-
ery confirm that FFF linacs can produce dosimetrically
equivalent plans [8] while reducing beam-on time by
more than 50% [9,10], and early clinical reports confirm
these findings [11-14]. However, limited clinical experi-
ence with this new technique has led some to question
the safety of this approach based on radiobiological
principles and clinical experience with high dose rate
brachytherapy applications.
The rationale for performing this study was based on
knowledge that while DNA damage repair can occur
during protracted low dose rate treatment, it may not
occur as readily during high dose rate treatments andFigure 1 Cross-beam profile. Cross beam profile of a conventional 10 me
profile of an unflattened photon beam (solid line) of equivalent energy. Th
at central axis.could yield higher rates of normal tissue toxicity. In
order to assess the toxicity with high-dose rate delivery,
we retrospectively evaluated the treatment related tox-
icity resulting from our early lung SBRT experience
utilizing a FFF linac operating at a maximal dose rate of
2400 monitor units per minute (MU/min).
Methods
Case selection
SBRT has been routinely performed at our institution
for lung malignancies since 2008; however, in September
2010 we commissioned a FFF linac (TrueBeam, Varian
Medical Systems, Palo Alto) capable of delivering 10MV
unflattened photons at a maximal dose rate of 2400
MU/min. Lung SBRT cases performed after September
2010 were almost exclusively performed using this ma-
chine, and these consecutively-treated patients formed
the basis of this study. For this analysis, SBRT was de-
fined as highly conformal radiotherapy delivered in 3–5
fractions of 6 Gy per fraction or higher with concomi-
tant image guidance and/or target motion tracking.
Treatment details
All patients were immobilized in the supine position
with a custom molded cradle (alpha cradle, Smithers
Medical Products Inc, North Canton, OH) and an over-
head arm device. All patients underwent CT-guided
simulation with respiratory motion assessment using
4D-CT; abdominal compression and other compression
devices were not used. Treatment planning was done ac-
cording to national published standards [5,6], however
the final dose schedule and treatment geometry were se-
lected at the discretion of the treating oncologist. Dose
schedule was influenced by tumor location; based upongavolt photon beam (dashed line) is compared to the cross beam
e unflattened beam has approximately four times higher dose rate
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within 2 cm of the proximal trachea-bronchial tree
were ineligible for 3-fraction regimens. All patients were
treated using 10 MV beams with either sliding-window
intensity modulated radiation therapy (IMRT) or volu-
metric modulated arc therapy (VMAT).
Standard pre-treatment image guidance consisting of
paired orthogonal KV X-rays matched to bony anatomy
followed by cone beam CT matched to soft tissue and
bony anatomy was used in all cases. If significant patient
motion was seen on surveillance video, the standard
pre-treatment image sequence was re-acquired. Intra-
fraction imaging to reaffirm target localization was rarely
used due to the shortened treatment times with the
increased dose rate.Table 1 Baseline characteristics
Number of patients (%)
Histology
Non-small cell lung cancer 56 (88%)
Other 6 (9%)
No pathology 2 (3%)
Dose schedule
6 Gy × 5 fractions 2 (3%)
8 Gy × 5 fractions 7 (11%)
9 Gy × 5 fractions 1 (1.5%)
10 Gy × 5 fractions 10 (16%)
10.5 Gy × 5 fractions 7 (11%)
12 Gy × 4 fractions 17 (27%)
18 Gy* × 3 fractions 19 (29%)
Other 1 (1.5%)
Tumor size
≤ 3 cm 36 (56%)
>3 cm 28 (44%)
SBRT indicationData analysis
After institutional review board approval, we reviewed
the electronic medical record for all FFF lung SBRT
cases treated at our institution from August 2010
through July 2012. Patients were eligible for inclusion if
they had at least one clinical assessment at least 30
days following SBRT. Pulmonary, cardiac, dermatologic,
neurologic, and gastrointestinal treatment related toxic-
ities were scored according to CTCAE version 4.0 [15].
Toxicity observed within 90 days of SBRT was catego-
rized as acute, whereas toxicity observed more than
90 days from SBRT was categorized as late. BED10 was
calculated assuming α/β of 10 by the following formula,
where n represents number of fractions, d represents
dose per fraction:
BED10 ¼ nd 1þ d=α=βð Þ
Factors predicted to influence risk of toxicity—including
tumor size, location, number of fractions, and BED10—were
examined to assess relationship to both acute and late grade
≥2 toxicity. Fisher’s exact test was used to assess tumor
location (central vs peripheral) and number of fractions
(3 vs more than 3), while logistic regression analysis was
used to assess the impact of BED10 and tumor size as
continuous variables on the development of toxicity
(STATA v.12.1, StataCorp, College Station, TX).Refused surgery 7 (11%)
Medically inoperable 47 (73%)




Baseline characteristics and treatment details for 64 evaluable patients treated
with FFF lung SBRT.
*Includes 20 Gy in 3 fractions without heterogeneity correction.Consent
All patients treated at the University of Alabama at
Birmingham Department of Radiation Oncology provide
informed consent for the collection of imaging and
dosimetry data related to treatment. The use of this data
for the current study was approved by the University of
Alabama at Birmingham Institutional Review Board.Results
Sixty-seven patients who underwent FFF SBRT from
August 2010 through July 2012 were identified; 3 pa-
tients were excluded as they were lost to follow up.
Therefore, 64 patients with adequate follow up were in-
cluded for analysis. Median SBRT dose was 48 Gy in 4
fractions (range: 30–60 Gy in 3–5 fractions). All patients
were treated using 10 MV beams with either sliding-
window intensity modulated radiation therapy (IMRT)
or volumetric modulated arc therapy (VMAT), chosen
at the discretion of the treating physician. The majority
(73%) of patients in this cohort were deemed medically
inoperable by a board certified thoracic surgeon (DM)
based on clinical assessment and pulmonary function
tests. The remaining patients were either surgically in-
curable (by virtue of unresectable disease or distant metas-
tases) or refused to consent to surgery. Table 1 summarizes
baseline tumor and treatment characteristics.
Acute toxicity results
Grade > =2 acute pulmonary toxicity was observed in six
of 64 patients (9%). Although events were mostly grade
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were no grade > =2 acute gastrointestinal, cardiac, skin,
or nerve-related events recorded (Table 2).
Late toxicity results
A subset of 49 patients with median follow up of
11.5 months (range 3–25 months) was assessable for late
toxicity. Pulmonary toxicities were the most common
late events, with asymptomatic grade 1 toxicity based on
imaging changes in the irradiated tissues being the most
frequently recorded event (20 of 49 patients eligible for
late toxicity analysis). Figure 2 displays the characteristic
imaging changes frequently observed 3–9 months fol-
lowing pulmonary SBRT and indicate grade 1 toxicity if
anaccompanied by clinical symptoms. Grade > =2 late
pulmonary events were recorded in 11 pateints (22%).
Of note, one grade 5 event (death) occurred in a 75 year
old medically inoperable patient with a 4.3 cm peripheral
lung tumor treated with 48 Gy in 4 fractions. The
patient was hospitalized for two episodes of pneumonia
and succumbed to sepsis during the second hospitalization.
Although this event was not definitely treatment related, it
was included because the inciting infection was localized to
the treated lobe. Pre- and post-treatment pulmonary
function scores did not indicate clinical deterioration
(FEV1 64% and 69% predicted; FVC 78% and 81% pre-
dicted, respectively). Overall, non-pulmonary toxic events
were rare and limited to three nerve-related late events;
there were no grade ≥2 late gastrointestinal, skin, or cardiac
toxicities (Table 2).
Data analysis
Logistical regression analysis of tumor size, number of
fractions, BED10 (all as continuous variables), and tumor
location (central vs peripheral) failed to demonstrate
a significant correlation with either acute or late grade > =2
pulmonary toxicity (Table 3). In addition, Fisher’s exact test
was used to examine the relationship of tumor location
(central vs peripheral) and number of fractions as a
dichotomous variable (3 vs >3) with both acute and lateTable 2 Treatment related toxicity
Acute toxicity (≤ 90 days)






Brachial plexopathy - -
chest wall pain - -
Type and number of toxic events for 64 patients with grade ≥2 acute toxicity (≤90
median follow up of 11.5 months.grade > =2 pulmonary toxicity. While tumor location did
not show an effect (p = 0.66 for acute and p = 0.48 for late
toxicity), number of SBRT fractions did suggest that 3 ver-
sus 4–5 fractions was associated with lower rates of late
pulmonary toxicity (p = 0.04 for late toxicity, p = 0.17 for
acute toxicity).
Discussion
This analysis demonstrates acceptable rates of significant
treatment related toxicity following lung SBRT with a
FFF linac operating at up to 2400 MU/min. Toxicity ob-
served in this cohort of unselected, consecutively treated
patients with lung cancer is comparable to that observed
in other published series [2,16,17]. In this experience,
acute toxicity at high dose rates is limited to pulmonary
events and was mild-moderate in severity.
Although mature data regarding late toxicity is not
available, this series provides an early assessment of late
treatment related toxicity after FFF SBRT. Grade 2 or
greater late pulmonary toxicity was observed in 22% of
patients at median follow up of 11.5 months. Severe tox-
icity (grade 4–5) was uncommon and limited to one
death due to pneumonia in a patient with underlying
COPD potentially attributable to radiation toxicity and
one case where temporary mechanical ventilation was
required after pneumonitis symptoms developed in a pa-
tient with an existing tracheotomy from prior laryngeal
cancer. The majority of observed late events were pul-
monary; however, 3 nerve-related events were recorded,
including one case of grade 3 brachial plexopathy which
resolved after a course of steroids and two other cases of
chest wall pain requiring short term narcotics.
On logistic regression analysis factors such as BED10,
tumor size, number of fractions, and tumor location did
not significantly predict for treatment related toxicity.
However, when using Fisher’s exact test to examine
number of fractions dichotomously, 3 fraction regimens
were found to be significantly associated with less late
pulmonary toxicity (p = 0.04, two-sided). This interaction
was unexpected since 3 fraction regimens deliver aLate toxicity (>90 days)
Grade 2 Grade 3 Grade 4 Grade 5
4 2 1 1
1 1 - -
1 - - -
- 1 - -
2 - - -
days) and subset of 49 patients with grade ≥2 late toxicity (>90 days) at
Figure 2 (See legend on next page.)
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Figure 2 Radiation associated imaging changes. Panels A and B show typical radiation changes that are apparent on chest CT approximately
3–9 months following SBRT. Images on the left show pre-treatment tumor and images on the right show post-SBRT changes. Both axial and
coronal planes are provided. The imaging changes depicted above are considered grade 1 radiation pneumonitis by the CTCAE v4.o criteria if
they are not associated with clinical symptomatology.
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more toxicity. A likely explanation for these results is
that our treatment planning process incorporates the
impact of variables such as dose, size, number of frac-
tions and location. For example, lesions would only be
planned for 3 fractions if the planner was confident that
the size and location were amenable to that approach.
Therefore, it is possible that our data reflects the suc-
cessful integration of previously identified treatment
planning goals to prevent known toxicities.
Although use of FFF SBRT is rising, there remains a
lack of toxicity data in the literature. In the only other
publication specifically addressing toxicity following FFF
lung SBRT, Scorsetti et al. report outcomes for 70 pa-
tients, 48 of whom had lung tumors [12]. Although sep-
arate toxicity was not reported for the lung patients, the
overall rate of acute toxicity was 9%, the same rate ob-
served in our experience. Building upon their earlier
work, our data includes a preliminary report on late
toxic events as well. Late toxic events were more com-
mon than acute events, with more than twice as many
events observed. Interestingly, not all patients with acute
toxicity went on to develop late effects and not all late
effects were preceded by acute toxicity, emphasizing the
need for longitudinal outcomes studies. Although ad-
equate assessment of late toxicity will require months or
years of follow up, it appears to be acceptable at 22%
grade > =2 and 10% grade > =3 in our experience.
The question of whether dose rate directly affects cell
survival is debatable. Seminal radiobiology studies in-
volving cell lines irradiated in vitro established the “dose
rate effect,” whereby cell survival decreases as the dose
rate increases [18]. Recent preclinical investigations draw
conflicting conclusions on the dose rate effect as it
relates to FFF linac generated photons. Lohse et al.
identified a strong dose rate effect when comparingTable 3 Statistical analysis
Acute toxicity (≤ 90 days)
Clinical factor OR 95
BED10 0.98 0.9
Tumor size 0.97 0.4
Number of fractions 2.90 0.7
Tumor location 0.53 0.1
Four clinical factors predicted to influence risk of pulmonary toxicity were analyzed
analyzed as continuous variables and tumor location was analyzed as a dichotomouclonogenic survival in two cell lines irradiated with 400
and 2400 MU/minute [19]. By contrast, Verbakel et al.
compared clonogenic survival following irradiation of
three different human cancer cell lines with either high
dose rate (unflattened) photons or conventional dose
rate (flattened) photons and found no difference in cell
survival after single or multi-fraction regimens [20].
Sørensen et al. failed to identify a dose rate effect in the
range of 5.01- 29.91 Gy/min [21]. Likewise, Ling et al.
point out that the dose rate effect is governed by beam-
on time, not by instantaneous dose rates, which may be
extremely high for a FFF linac [22]. In an earlier study at
our institution (involving some of the same patients), we
found that actual beam-on time for FFF lung SBRT was
on the order of 2–3 minutes [14]. Therefore, assuming
fraction doses of 6–18 Gy, the dose rates delivered in
this study were 2–9 Gy/min and well within the range
examined by Sørensen et al.
In the midst of a basic controversy on whether dose
rate affects cell survival, an equally important clinical
question remains: does dose rate affect toxicity? Data
from this series does not suggest that high dose rate de-
livery yields elevated treatment related toxicity in lung
SBRT. There are likely several explanations for this find-
ing. As previously noted, the absolute dose and dose
rates associated with FFF SBRT likely fall into a range
where changes are not as significant as those observed
in earlier studies using low dose rate experiments.
Another sensible explanation for the acceptable toxicity
observed is diligent treatment planning with a focus on
organ avoidance and gradient index. All patients in this
study were treated at an academic medical center from
2010 onward and national treatment planning guidelines
aimed at reducing toxicity were adhered to in all cases.
Indeed, as demonstrated by Timmerman et al. in a phase
II study and echoed in a widely-publicized case report inLate toxicity (>90 days)





using logistical regression. BED10, tumor size, and number of fractions were
s variable (Central vs peripheral).
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avoidance remains a chief concern and determinant of
toxicity [2,23].
Despite concerns regarding dose rate and toxicity, FFF
treatment carries several promising advantages over
conventional flattened photon beam therapy. Preclinical
research suggests unflattened beams generate less neu-
tron contamination, lower doses outside the field edge,
and less MLC leakage than flattened beams [10,24,25].
Additionally, some have suggested FFF beams could lead
to lower rates of secondary malignancies given the
observed 70% decrease in scattered photon dose [26].
Some have hypothesized that FFF SBRT will prove to be
more efficacious than conventional dose rate therapy
owing to the same radiobiological principles discussed
earlier. Additionally, it has been shown that FFF SBRT
shortens treatment delivery times [13,14], thereby redu-
cing the opportunity for intrafraction motion which
could further improve outcomes. Further work will be
necessary to determine the clinical significance of these
above noted potential advantages for FFF therapy.
Although this is the largest series of toxicity results
following lung SBRT with unflattened photons, we
recognize several limitations in this study. First, toxicity
was scored retrospectively based on clinical documenta-
tion and therefore could under- or over-estimate tox-
icity. Secondly, given the retrospective nature, it is
possible that some patients with toxicity did not report
back to clinic, which would further contribute to under-
estimation of toxicity. As previously mentioned, the
relatively short follow up of 11.5 months limits interpret-
ation of late toxicity results and ongoing analysis is
needed. Lastly, small patient numbers hinder the power
of this study to interpret confounding factors that may
independently predict toxicity.Conclusions
In this early clinical experience, FFF lung SBRT at up to
2400 MU/min yielded acceptable rates of grade ≥2
toxicity. Continued assessment to study the incidence of
late effects and further investigation into possible dosi-
metric correlates of toxicity is warranted.Abbreviations
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